Madam Therapeutics has been awarded a EUROSTARS subsidy. The new NASAMP program will start January 1st 2016.
The aim of this project is to develop a nasal therapy with antimicrobial peptides (AMPs) to eradicate MRSA carriage. The synthetic AMPs that were previously developed by Madam Therapeutics (Madam) and Leiden University Medical Center (LUMC) have shown to be fully effective against antibiotic-resistant bacterial strains, including MRSA. At the end of this project, an AMP-based nasal therapy will be available, with associated Proof-of-Mechanism and safety data package.
Other partners in the project are SiSaf Ltd from the UK who provide expertise in formulation, as well as SiSaf’s proprietary nanosilicon platform technology for stable and controlled drug delivery. The products are tested at Toxi-Coop in Hungary. Toxi-Coop combines German precision and Hungarian loadability in a state-of-the-art facility with scientific staff averaging ~20 years of experience.